Research programme: CNS disorders therapeutics - Rexahn

Drug Profile

Research programme: CNS disorders therapeutics - Rexahn

Alternative Names: RX-10,000

Latest Information Update: 06 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revaax Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Neurological disorders; Neuropathic pain

Most Recent Events

  • 19 May 2005 Preclinical trials in Anxiety disorders in USA (unspecified route)
  • 19 May 2005 Preclinical trials in Cognition disorders in USA (unspecified route)
  • 19 May 2005 Preclinical trials in Depression in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top